Sight Sciences (SGHT) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free SGHT Stock Alerts $5.49 +0.07 (+1.29%) (As of 01:23 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | americanbankingnews.comSight Sciences (NASDAQ:SGHT) Rating Reiterated by Needham & Company LLCMay 6, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call TranscriptMay 5, 2024 | americanbankingnews.comPiper Sandler Reiterates Neutral Rating for Sight Sciences (NASDAQ:SGHT)May 5, 2024 | americanbankingnews.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesMay 4, 2024 | finance.yahoo.comSight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | finance.yahoo.comQ1 2024 Sight Sciences Inc Earnings CallMay 3, 2024 | marketbeat.comSight Sciences (NASDAQ:SGHT) Given "Neutral" Rating at Piper SandlerPiper Sandler reaffirmed a "neutral" rating and issued a $6.00 price target (up previously from $5.00) on shares of Sight Sciences in a research report on Friday.May 2, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comSight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial GuidanceMay 1, 2024 | markets.businessinsider.comSight Sciences earnings preview: what to expectApril 29, 2024 | globenewswire.comSight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma SurgeryApril 22, 2024 | finance.yahoo.comWith 34% ownership, Sight Sciences, Inc. (NASDAQ:SGHT) has piqued the interest of institutional investorsApril 18, 2024 | globenewswire.comSight Sciences to Report First Quarter Financial Results on May 2, 2024April 13, 2024 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Sees Significant Decrease in Short InterestSight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 1,290,000 shares, a decrease of 20.9% from the March 15th total of 1,630,000 shares. Approximately 4.9% of the company's shares are short sold. Based on an average daily trading volume, of 215,100 shares, the short-interest ratio is presently 6.0 days.April 12, 2024 | investing.comSight Sciences reports glaucoma surgery study resultsApril 10, 2024 | globenewswire.comSight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with GlaucomaApril 10, 2024 | marketbeat.comSight Sciences' (SGHT) "Hold" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Wednesday.April 10, 2024 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Rating of "Hold" by BrokeragesSight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been assigned an average recommendation of "Hold" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recApril 5, 2024 | insidertrades.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells 3,128 Shares of StockApril 4, 2024 | marketbeat.comDavid Badawi Sells 3,128 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) StockSight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 3,128 shares of the business's stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $15,890.24. Following the transaction, the chief technology officer now owns 1,762,776 shares in the company, valued at $8,954,902.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.April 2, 2024 | globenewswire.comSight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingMarch 27, 2024 | finance.yahoo.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 26, 2024 | globenewswire.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 16, 2024 | finance.yahoo.comSGHT Apr 2024 5.000 callMarch 8, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Sight Sciences Inc Earnings CallMarch 8, 2024 | marketbeat.comSight Sciences (NASDAQ:SGHT) Releases Earnings Results, Beats Estimates By $0.13 EPSSight Sciences (NASDAQ:SGHT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.13. Sight Sciences had a negative net margin of 74.55% and a negative return on equity of 43.37%. The company had revenue of $18.75 million for the quarter, compared to the consensus estimate of $18.70 million. During the same period in the prior year, the firm posted ($0.35) EPS.March 7, 2024 | finance.yahoo.comSight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce ExpensesMarch 7, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comSight Sciences: Q4 Earnings InsightsMarch 7, 2024 | msn.comSight Sciences GAAP EPS of -$0.22 beats by $0.12, revenue of $18.8M misses by $0.6MMarch 7, 2024 | globenewswire.comSight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial GuidanceMarch 6, 2024 | benzinga.comSight Sciences's Earnings: A PreviewFebruary 23, 2024 | finance.yahoo.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderFebruary 23, 2024 | finance.yahoo.comUVM Health Network and UnitedHealthcare reach last minute agreement on coverageFebruary 22, 2024 | globenewswire.comSight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024February 21, 2024 | finance.yahoo.comTen-Year Low Volatility Has Locals Piling Into Brazilian RealFebruary 21, 2024 | finance.yahoo.comSight Sciences (SGHT) to Expand in Europe With New LaunchFebruary 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Integer Holdings (ITGR) and Pacific Biosciences (PACB)February 15, 2024 | finanznachrichten.deSight Sciences, Inc.: Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | finance.yahoo.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | finance.yahoo.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | globenewswire.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 11, 2024 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Average Rating of "Hold" from AnalystsSight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been given an average recommendation of "Hold" by the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendationFebruary 7, 2024 | marketbeat.comFirst Eagle Investment Management LLC Has $1.98 Million Holdings in Sight Sciences, Inc. (NASDAQ:SGHT)First Eagle Investment Management LLC grew its holdings in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 45.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 587,297 shares of the company's stock after acquiring an additional 183February 3, 2024 | msn.comSight Sciences Executive Compensation Adjustments for 2024January 19, 2024 | marketbeat.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells 3,414 Shares of StockSight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 3,414 shares of Sight Sciences stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $5.16, for a total value of $17,616.24. Following the completion of the transaction, the chief technology officer now directly owns 1,642,157 shares of the company's stock, valued at $8,473,530.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 17, 2024 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Average Rating of "Hold" from BrokeragesShares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have earned an average recommendation of "Hold" from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and one has gJanuary 9, 2024 | finanznachrichten.deSight Sciences, Inc.: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial HighlightsJanuary 8, 2024 | finance.yahoo.comSight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights Get Sight Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… SGHT Media Mentions By Week SGHT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGHT News Sentiment▼1.220.57▲Average Medical News Sentiment SGHT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGHT Articles This Week▼12▲SGHT Articles Average Week Get Sight Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INO News TLSI News GUTS News UTMD News ANGO News RCEL News CERS News TCMD News LUNG News PROF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGHT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
